P68 PACIFIC: a phase III, randomised, multicentre, dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a in patients with Child's A or B cirrhosis in chronic hepatitis C virus infection

S Tanwar; M Wright; G Foster; S Ryder; P Mills; M Cramp; J Parkes; W Rosenberg

doi:10.1136/gut.2010.223362.94

P68 PACIFIC: a phase III, randomised, multicentre, dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a in patients with Child's A or B cirrhosis in chronic hepatitis C virus infection

S Tanwar
, M Wright
, G Foster
, S Ryder
, P Mills
, M Cramp
, J Parkes
, W Rosenberg

Peninsula Medical School

Research output: Contribution to journal › Article › peer-review

Original language	English
Number of pages	0
Journal	Gut
Volume	59
Issue number	0
DOIs	https://doi.org/10.1136/gut.2010.223362.94
Publication status	Published - 1 Sept 2010

Keywords

32 Biomedical and Clinical Sciences
3202 Clinical Sciences
Clinical Research
Infectious Diseases
Liver Disease
Chronic Liver Disease and Cirrhosis
Hepatitis - C
Digestive Diseases
Emerging Infectious Diseases
Hepatitis
Clinical Trials and Supportive Activities
6 Evaluation of treatments and therapeutic interventions
6.1 Pharmaceuticals
Infection
3 Good Health and Well Being

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/gut.2010.223362.94

Cite this

Tanwar, S., Wright, M., Foster, G., Ryder, S., Mills, P., Cramp, M., Parkes, J., & Rosenberg, W. (2010). P68 PACIFIC: a phase III, randomised, multicentre, dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a in patients with Child's A or B cirrhosis in chronic hepatitis C virus infection. Gut, 59(0). https://doi.org/10.1136/gut.2010.223362.94

@article{19ee6629b1c9438a91364e1172030961,

title = "P68 PACIFIC: a phase III, randomised, multicentre, dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a in patients with Child's A or B cirrhosis in chronic hepatitis C virus infection",

keywords = "32 Biomedical and Clinical Sciences, 3202 Clinical Sciences, Clinical Research, Infectious Diseases, Liver Disease, Chronic Liver Disease and Cirrhosis, Hepatitis - C, Digestive Diseases, Emerging Infectious Diseases, Hepatitis, Clinical Trials and Supportive Activities, 6 Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, 3 Good Health and Well Being",

author = "S Tanwar and M Wright and G Foster and S Ryder and P Mills and M Cramp and J Parkes and W Rosenberg",

year = "2010",

month = sep,

day = "1",

doi = "10.1136/gut.2010.223362.94",

language = "English",

volume = "59",

journal = "Gut",

issn = "0017-5749",

publisher = "BMJ Publishing Group",

number = "0",

}

Tanwar, S, Wright, M, Foster, G, Ryder, S, Mills, P, Cramp, M, Parkes, J & Rosenberg, W 2010, 'P68 PACIFIC: a phase III, randomised, multicentre, dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a in patients with Child's A or B cirrhosis in chronic hepatitis C virus infection', Gut, vol. 59, no. 0. https://doi.org/10.1136/gut.2010.223362.94

P68 PACIFIC: a phase III, randomised, multicentre, dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a in patients with Child's A or B cirrhosis in chronic hepatitis C virus infection. / Tanwar, S; Wright, M; Foster, G et al.
In: Gut, Vol. 59, No. 0, 01.09.2010.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - P68 PACIFIC: a phase III, randomised, multicentre, dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a in patients with Child's A or B cirrhosis in chronic hepatitis C virus infection

AU - Tanwar, S

AU - Wright, M

AU - Foster, G

AU - Ryder, S

AU - Mills, P

AU - Cramp, M

AU - Parkes, J

AU - Rosenberg, W

PY - 2010/9/1

Y1 - 2010/9/1

KW - 32 Biomedical and Clinical Sciences

KW - 3202 Clinical Sciences

KW - Clinical Research

KW - Infectious Diseases

KW - Liver Disease

KW - Chronic Liver Disease and Cirrhosis

KW - Hepatitis - C

KW - Digestive Diseases

KW - Emerging Infectious Diseases

KW - Hepatitis

KW - Clinical Trials and Supportive Activities

KW - 6 Evaluation of treatments and therapeutic interventions

KW - 6.1 Pharmaceuticals

KW - Infection

KW - 3 Good Health and Well Being

U2 - 10.1136/gut.2010.223362.94

DO - 10.1136/gut.2010.223362.94

M3 - Article

SN - 0017-5749

VL - 59

JO - Gut

JF - Gut

IS - 0

ER -